Active Ingredient(s): Tirbanibulin
FDA Approved: * December 14, 2020
Pharm Company: * ALMIRALL
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Klisyri Overview

Tirbanibulin, sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis on the face or scalp.[1][2] The most common side effects include local skin reactions, application site pruritus, and application site pain.[1][2] Tirbanibulin was approved for medical use in the United States in December 2020.[2][3][4] The U.S. Food and Drug Administration (FDA) ...

Read more Klisyri Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tirbanibulin

Recent Klisyri Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Ointment: 1%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Klisyri: (1 result)

Sorted by National Drug Code
  • 16110-391 Klisyri 10 mg/g Topical Ointment by Almirall, LLC

Other drugs which contain Tirbanibulin or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 4 August 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA